Abstract
Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer.
Citation: Coosemans A, Vergote I, Van Gool SW. Dendritic cell-based immunotherapy in ovarian cancer. OncoImmunology 2013; 2:e27059; 10.4161/onci.27059
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgements
An Coosemans is a postdoctoral research fellow supported by the FWO-V; Ignace Vergote and Stefaan W Van Gool are senior clinical investigators supported by the FWO-V.